To investigate this hypothesis, we first characterized the relative amount of cell surface CD38 receptor in 32 Human Myeloma Cell lines (HMCLs) representative of MM molecular and mutational heterogeneity, by calculating their CD38 antibody binding capacity (ABC). Here, CD38 is linked to Miyoshi myopathy.